• Trump ordered a 100% tariff on patented drugs from companies without pricing agreements.
• Manufacturers have 120 days to comply or face hefty tariffs.
• Countries like the UK and EU will see reduced tariff rates under new agreements.

The Trump administration announced a 100% tariff on certain imported pharmaceuticals, aimed at boosting domestic production and reducing drug prices. This measure is applicable to patented drugs produced in countries without tariff agreements with the U.S. Companies can avoid the full tariff by signing "most favored nation" pricing agreements or committing to establish manufacturing facilities in the U.S., reports Reuters and BBC.

Under the new order, larger pharmaceutical companies will have 120 days to negotiate agreements before the tariffs take effect, while smaller companies will have 180 days, according to statements from Al Jazeera and India Times.

The tariffs will not apply to generic medicines for now, and exemptions include countries like the EU, Japan, and South Korea, which face reduced tariffs of 15%, while the UK has negotiated a zero-rate for three years if it boosts domestic production. This strategic tariff imposition is framed as a national security move to ensure essential medicines are produced domestically, as outlined by Reuters and Los Angeles Times.

Experts predict that smaller pharmaceutical companies may bear the brunt of these tariffs, potentially leading to higher prices for consumers. Industry insiders, like Stephen Ubl of the Pharmaceutical Research and Manufacturers of America, warn that the tariffs could jeopardize billions in U.S. investments and increase healthcare costs for American families, as discussed in Los Angeles Times and BBC.

The administration's tariffs are intended to spur billions in investments for domestic manufacturing, hoping to encourage major drugmakers to relocate production to the United States. However, the effectiveness and implications of these tariffs remain under scrutiny by economic analysts and industry leaders, as noted by Reuters and India Times.